Atlas Trials

Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

Clinical trial NCT06563245 · RECRUITING

Trial details

NCT number
NCT06563245
Sponsor
Children's Cancer Group, China
Status
RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Classical Hodgkin LymphomaChildAdolescentYoung AdultMetabolic ResponseSurvivalTreatmentBrentuximab VedotinPET Scan
Start date
2024-09-25
Primary completion
2029-11-15
Enrollment
96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.